Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
|Articles|April 1, 2018
HIV and the Opioid Epidemic
Author(s)Jaime Rosenberg
As the opioid epidemic persists as a public health crisis in the United States, there has been growing concern the injection drug use will affect infectious disease, as it increases the risk of infections, such as HIV. A graphic series from Kaiser Family Foundation took a look at the interaction between the nation's HIV and opioid epidemics. Here are 5 take aways.
Advertisement
As the opioid epidemic persists as a public health crisis in the United States, there has been growing concern the injection drug use will affect infectious disease, as it increases the risk of infections, such as HIV. A
Advertisement
Related to this article
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5